Get the Stockscreener App
4.25
1.67%
+0.07
Pre-market:
4.25
Acelyrin Inc stock is currently priced at $4.25, with a 24-hour trading volume of 1.14M.
It has seen a +1.67% increased in the last 24 hours and a -36.19% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.21 pivot point. If it approaches the $4.27 resistance level, significant changes may occur.
Previous Close:
$4.18
Open:
$4.19
24h Volume:
1.14M
Market Cap:
$420.38M
Revenue:
-
Net Income/Loss:
$-381.64M
P/E Ratio:
-0.3506
EPS:
-12.1221
Net Cash Flow:
$-182.00M
1W Performance:
-7.00%
1M Performance:
-36.19%
6M Performance:
-53.45%
1Y Performance:
+0.00%
1D Range:
$4.19
$4.38
52W Range:
$4.14
$29.88
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-730-0360
Address
4149 Liberty Canyon Road, Agoura Hills
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
GlobeNewswire Inc.
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
Zacks Investment Research
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
GlobeNewswire Inc.
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
GlobeNewswire Inc.
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
GlobeNewswire Inc.
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Acelyrin Inc Stock (SLRN) Financials Data
Acelyrin Inc (SLRN) Net Income 2024
SLRN net income (TTM) was -$381.64 million for the quarter ending December 31, 2023, a -489.21% decrease year-over-year.
Acelyrin Inc (SLRN) Cash Flow 2024
SLRN recorded a free cash flow (TTM) of -$182.00 million for the quarter ending December 31, 2023, a -195.84% decrease year-over-year.
Acelyrin Inc (SLRN) Earnings per Share 2024
SLRN earnings per share (TTM) was -$3.8353 for the quarter ending December 31, 2023, a -21.05% decline year-over-year.
Acelyrin Inc Stock (SLRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Feb 20 '24 |
Sale |
7.60 |
15,701 |
119,403 |
1,587,335 |
| Lin Shao-Lee | Chief Executive Officer |
Jan 02 '24 |
Sale |
7.41 |
10,691 |
79,188 |
1,603,036 |
| Westlake BioPartners Fund II, | 10% Owner |
May 09 '23 |
Buy |
18.00 |
1,250,000 |
22,500,000 |
9,790,729 |
| SEIDENBERG BETH C | Director |
May 09 '23 |
Buy |
18.00 |
1,250,000 |
22,500,000 |
9,790,729 |
| SEIDENBERG BETH C | Director |
May 09 '23 |
Buy |
18.00 |
60,000 |
1,080,000 |
60,000 |
| Gosebruch Henry O | Director |
May 09 '23 |
Buy |
18.00 |
50,000 |
900,000 |
50,000 |
| Svoronos Dawn | Director |
May 09 '23 |
Buy |
18.00 |
15,000 |
270,000 |
15,000 |
| Peloso Paul | Chief Medical Officer |
May 09 '23 |
Buy |
18.00 |
6,000 |
108,000 |
6,000 |
| Dier Mardi | CFO and CBO |
May 09 '23 |
Buy |
18.00 |
5,556 |
100,008 |
5,556 |
| Kim Mina | Chief Legal & Admin. Officer |
May 09 '23 |
Buy |
18.00 |
5,000 |
90,000 |
5,000 |
About Acelyrin Inc
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
3.18%
Cap:
|
Volume (24h):